Similarly, we have recently shown that mTOR inhibition with everolimus in the adjuvant setting after definitive treatment of locally advanced HNSCC lesions reduces significantly tumor relapse, specifically in HPV− cases (8). Here, MTOR is linked to head and neck squamous cell carcinoma.